首页> 美国卫生研究院文献>Open Forum Infectious Diseases >Performance Verification of the Accelerate Pheno™ System for Rapid Identification and Antimicrobial Susceptibility Testing from Positive Blood Culture in a Pediatric Population
【2h】

Performance Verification of the Accelerate Pheno™ System for Rapid Identification and Antimicrobial Susceptibility Testing from Positive Blood Culture in a Pediatric Population

机译:从儿科人群的阳性血液培养中快速鉴定和抗菌药敏测试的Accelerate Pheno™系统的性能验证

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundEarly targeted antibiotic therapy is crucial when treating pediatric patients with bacteremia. While identification (ID) and antimicrobial susceptibility testing (AST) of bloodstream pathogens are critical to optimizing therapy, conventional methods can take days resulting in inappropriate use of broad-spectrum antibiotics. The automated Accelerate Pheno™ system (AXDX) provides ID in <90 minutes and AST in <7 hours directly from positive blood culture (PBC), enabling clinicians to optimize antibiotic therapy sooner to improve patient outcomes. In addition, the unique AXDX Monomicrobial call effectively rules out polymicrobial samples by indicating only one bacteria is present in the PBC. This study verifies AXDX performance compared with current laboratory ID and AST methods.
机译:背景在治疗小儿菌血症患者时,早期靶向抗生素治疗至关重要。虽然对血流病原体的识别(ID)和抗菌药敏测试(AST)对于优化治疗至关重要,但传统方法可能需要几天的时间,导致不恰当地使用广谱抗生素。自动化的Accelerate Pheno™系统(AXDX)可从阳性血培养(PBC)直接在90分钟内提供ID,在7小时内提供AST,从而使临床医生能够更快地优化抗生素治疗以改善患者预后。此外,独特的AXDX Monomicrobial调用通过指示PBC中仅存在一种细菌有效地排除了微生物样品。与当前的实验室ID和AST方法相比,本研究验证了AXDX的性能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号